What is Zhejiang Ausun Pharmaceutical Co., Ltd.'s (603229.SS) StockRank?

MoatMap's StockRank for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is 43/100, with a Hold signal. This is a composite score combining Quality (57), Value (23), and Momentum (55) factor ranks across MoatMap's 19,000+ stock universe.

Does Zhejiang Ausun Pharmaceutical Co., Ltd. have an economic moat?

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Zhejiang Ausun Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Zhejiang Ausun Pharmaceutical Co., Ltd. in?

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603229.SS

HOLDFLAG

Zhejiang Ausun Pharmaceutical Co., Ltd. · Healthcare · China · $1.2B · Avg Vol: $15M/d

StockRank

P/E (TTM)

59.9x

ROE

4.6%

D/E

0.2x

Dividend %

0.8%

Director Trades · 180d

None in 180d →

Buybacks · 180d

$7.4M · 1d →

AI CONVICTION THESIS

A high-quality Chinese API and CDMO player with strong manufacturing capabilities. While it fits the CDMO pricing power cycle, it faces geopolitical headwinds from Western legislative scrutiny (e.g., the Biosecure Act), making it a FLAG rather than a high-conviction APPROVE.

COMPANY DESCRIPTION

Zhejiang Ausun Pharmaceutical Co., Ltd. manufactures active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and provides CDMO services. The company specializes in high-barrier, complex chemical synthesis, serving global pharmaceutical companies in regulated markets such as the US, Europe, and Japan. Its competitive advantage lies in its strict compliance with international cGMP standards, robust R&D in green chemistry, and strong customer stickiness due to regulatory filing requirements.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	113M	121M	118M	117M	1.2%
EPS	0.04	0.05	0.04	0.02	-18.2%
Shares	788M	830M	830M	830M	+5.4%
Debt	36M	45M	40M	67M	23.6%
Equity	216M	317M	336M	335M	15.8%
Op CF	18M	33M	26M	23M	9.1%
Inv CF	-26M	-26M	-18M	-9M	—
Fin CF	14M	69M	-16M	7M	—

PRICE (1M)-14.5%

SMA 50SMA 200

$1.24

RSI (14)

8.9

52W High

$1.85

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

6.2%61.0

ROE

4.6%55.1

GP/Assets

13.3%32.1

Op. Margin

41.2%97.0

FCF/Assets

-3.4%39.1

Piotroski

—83.5

Int. Cover

18.1x73.4

D/E Ratio

0.21x51.4

Current Ratio

2.64x47.9

Value

P/E (TTM)

59.9x16.4

EV/EBITDA

32.9x10.6

P/FCF

—N/A

P/B

2.9x40.7

P/S

8.8x29.0

Div Yield

0.8%20.4

Momentum

52W High %

67%51.9

RS 6M

-21%52.9

SMA 50/200

0.98x57.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—87.6

Q Growth

-19%25.5

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

20.0x

Gross Margin

51.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603229.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603229.SS	Zhejiang Ausun Pharmaceutical Co., Ltd.(you)	$1.2B	43	HOLD
300497.SZ	Jiangxi Fushine Pharmaceutical Co., Ltd.	$1.2B	41	HOLD
688739.SS	Liaoning Chengda Biotechnology Co.,Ltd.	$1.3B	42	HOLD
688658.SS	Youcare Pharmaceutical Group Co., Ltd.	$1.2B	39	HOLD
600866.SS	Star Lake Bioscience Co., Inc.Zhaoqing Guangdong	$1.2B	46	HOLD
688366.SS	Shanghai Haohai Biological Technology Co., Ltd.	$1.1B	48	HOLD
2171.HK	CARsgen Therapeutics Holdings Limited	$1.3B	39	HOLD
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
301080.SZ	Acrobiosystems Co.,Ltd.	$1.0B	38	HOLD
301207.SZ	Hualan Biological Vaccine Inc.	$1.6B	47	HOLD

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) — Stock Score Summary

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) has a MoatMap StockRank of 43/100 based on Quality (57/100), Value (23/100), and Momentum (55/100) factor scores. The current signal is HOLD. A high-quality Chinese API and CDMO player with strong manufacturing capabilities. While it fits the CDMO pricing power cycle, it faces geopolitical headwinds from Western legislative scrutiny (e.g., the Biosecure Act), making it a FLAG rather than a high-conviction APPROVE.

Key Financial Metrics

Price	$1.24
Market Cap	$1.2B
P/E (TTM)	59.86
P/E (Forward)	19.95
Price/Book	2.92
Return on Equity	4.6%
Return on Invested Capital	6.2%
Debt/Equity	20.54
Gross Margin	51.6%
Operating Margin	41.2%
Revenue Growth	0.7%
Dividend Yield	0.8%
Free Cash Flow	$-2M

Zhejiang Ausun Pharmaceutical Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Zhejiang Ausun Pharmaceutical Co., Ltd.’s (603229.SS) StockRank?: MoatMap’s StockRank for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is 43/100, with a Hold signal. It is a composite of Quality (57), Value (23), and Momentum (55) factor ranks across MoatMap’s 19,000+ stock universe.
Does Zhejiang Ausun Pharmaceutical Co., Ltd. have an economic moat?: Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Zhejiang Ausun Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Zhejiang Ausun Pharmaceutical Co., Ltd. in?: Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).